Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Research
General Research
- When HIV Regimens Fail, Resistance Risk Appears Higher on NNRTIs Than Protease Inhibitors (October 3, 2008)
From aidsmap.com - Drug Watch: Next-Generation NNRTIs: Etravirine and Rilpivirine (Winter 2008)
To read PDF, click here.
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - NNRTIs: The Next Generation Approaches (Part I) (December 14, 2006)
From The Body PRO - NNRTIs: The Next Generation Approaches (Part II) (December 14, 2006)
From The Body PRO - People With History of Depression More Likely to Stop Efavirenz Due to Mental Health Problems (July 26, 2006)
From aidsmap.com - HIV JournalView: Adherence, Viral Fitness and NNRTI and PI Resistance (February/March 2006)
Bangsberg et al find that NNRTIs are more likely to suppress HIV than a single PI, but are also more vulnerable to resistance at low adherence levels.
From The Body PRO - HIV JournalView: Low-Level Viremia May Slowly Breed Resistance, but Watch Out for NNRTIs (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO
Efavirenz (Sustiva, Stocrin)
- Clinical Trials Using Efavirenz (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Literature Citations for Efavirenz (Regularly Updated)
From U.S. National Institutes of Health - Prospective, Randomized, Open-Label Trial of Efavirenz vs. Lopinavir/Ritonavir in HIV+ Treatment-Naive Subjects With CD4+ Less Than 200 (February 4, 2010)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention - Sustiva + Ginkgo: Possible Recipe for Resistance, Doctors Report (May 21, 2009)
From aidsmap.com - Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Efavirenz Significantly Reduces Levels of Some Oral Contraceptives (November/December 2008)
In HIV Treatment Bulletin, from HIV i-Base - Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here.
In Project Inform Perspective, from Project Inform - Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
In aidsmap.com - Sustiva Study Finds Ethnicity, Quality of Life Predict Treatment Outcomes (April 1, 2008)
From Project Inform - Efavirenz to Nevirapine Switch in HIV-1-Infected Patients with Dyslipidemia: A Randomized, Controlled Study (June 6, 2007)
Small French study finds that switching NNRTIs may somewhat reduce abnormally high LDL cholesterol levels.
In Clinical Infectious Diseases - Metabolic Complications: A CROI Round-Up (February 28, 2007)
Includes an analysis of research examining lopinavir/ritonavir vs. efavirenz, the use of growth hormone releasing factor to treat fat gain, the link between cardiovascular disease and HIV treatment, the use of ezetimibe (a choleserol-reducing agent) and the latest on bone health in HIV-infected patients.
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Baseline NNRTI Resistance and Virologic Failure in Treatment-Naive Patients on Efavirenz: An Interview With Daniel Kuritzkes, M.D. (February 26, 2007)
In Exclusive Coverage of the 14th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Efavirenz-Based Regimens Best Lopinavir/Ritonavir Regimens in Head-to-Head Trial (August 17, 2006)
In XVI International AIDS Conference - ACTG 384 Substudy: DEXA Outcomes in Antiretroviral-Naive Patients Randomized to Efavirenz or Nelfinavir or Both Plus Nucleoside Backbone (August 16, 2006)
In XVI International AIDS Conference - Data Supports Bioequivalence for Once-Daily, Single-Pill, Fixed-Dose Combination of Sustiva and Truvada, Drug Companies Announce (January 9, 2006)
Filing of a new drug application is expected in the second quarter of 2006.
To read PDF, click here.
From Bristol-Myers Squibb Company and Gilead Sciences, Inc. - HIV JournalView: Efavirenz Has No Significant, Lasting Impact on Neuropsychological Performance (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO - Gilead's Fixed-Dose Combination of Truvada + Efavirenz Not Yet Bioequivalent to Drugs Alone (August 10, 2005)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - High Efavirenz Concentrations Affect Sleep, Spanish Study Finds (February 2004)
From International Association of Physicians in AIDS Care
Nevirapine (Viramune)
- Literature Citations for Nevirapine (Regularly Updated)
From U.S. National Institutes of Health - Clinical Trials Using Nevirapine (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Safety and Tolerability of Nevirapine-Based Antiretroviral Therapy in HIV-Infected Patients Receiving Fluconazole for Cryptococcal Prophylaxis: A Case-Control Study (October 2005)
Abstract of a study in the Aug. 24, 2005 issue of BMC Infectious Diseases finding that nevirapine should not be contraindicated for advanced AIDS patients receiving fluconazole.
From International Association of Physicians in AIDS Care - Nevirapine Matches Atazanavir/Ritonavir in 48-Week Study (July 29, 2009)
Nevirapine has equivalent efficacy to atazanavir/ritonavir when combined with tenofovir and emtricitabine in treatment-naive patients, results from the ARTEN study show.
From aidsmap.com - Nevirapine Sports Better Lipid Profile Than Atazanavir, Study Suggests (July 20, 2009)
Patients taking nevirapine may have a lower risk of developing cardiovascular disease than those taking ritonavir-boosted atazanavir, according to a 569-patient study by European researchers. The study found that although nevirapine's efficacy was non-inferior to that of atazanavir, nevirapine appeared to have a more favorable lipid profile.
In Kaiser Daily U.S. HIV/AIDS Report, from Henry J. Kaiser Family Foundation - Jens Lundgren, M.D., Discusses New Findings Regarding MI Risk of Specific Antiretrovirals (February 9, 2009)
The latest data from D:A:D indicate that lopinavir/ritonavir does increase myocardial infarction risk, but efavirenz, nevirapine and tenofovir do not. In this interview, Jens Lundgren, M.D., and HIV advocate Jeff Berry take part in a fascinating discussion on the new findings and their possible underlying causes.
In The 16th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Switch to Viramune Safe for Some Who Can't Tolerate Sustiva (December 2008)
To read PDF, click here.
In Project Inform Perspective, from Project Inform - Efavirenz to Nevirapine Switch in HIV-1-Infected Patients with Dyslipidemia: A Randomized, Controlled Study (June 6, 2007)
Small French study finds that switching NNRTIs may somewhat reduce abnormally high LDL cholesterol levels.
In Clinical Infectious Diseases - Once-Daily Lamivudine + Nevirapine + Tenofovir Leads to High Failure Rates in Treatment-Naive Individuals (March 8, 2007)
In aidsmap.com - Nevirapine-Associated Toxicity Less Frequent in Non-Naive Patients (August 17, 2006)
In XVI International AIDS Conference - Hepatotoxicity in IDUs and Non-IDUs Receiving Nevirapine-Based HAART (August 16, 2006)
In XVI International AIDS Conference - Nevirapine Resistance May Persist in Some Pregnant Women, Study Finds (May 3, 2006)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation - In Uganda, Three-NRTI Regimen Including Abacavir Is Better Tolerated Than Nevirapine-Based Regimen (February 7, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections - Rash, NNRTIs and the 2NN Study (February/March 2005)
Rash appears more common among people taking nevirapine once a day.
From The Body PRO - HDL Benefit Is Maintained With Extension of Nevirapine and Efavirenz Treatment in 2NN Study
In XV International AIDS Conference
Clinical Management
Clinical Management
  |